Last reviewed · How we verify

DTaP-IPV-HB-Hib vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-IPV-HB-Hib vaccine is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children. Also known as: Hexyon®/Hexacima®.

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTaP-IPV-HB-Hib vaccine
Also known asHexyon®/Hexacima®
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP-IPV-HB-Hib is a combination vaccine containing inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, hepatitis B surface antigen, and Haemophilus influenzae type b conjugate. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, providing protection against six serious infectious diseases. The vaccine is designed for primary immunization and booster doses in infants and young children.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV-HB-Hib vaccine

What is DTaP-IPV-HB-Hib vaccine?

DTaP-IPV-HB-Hib vaccine is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

How does DTaP-IPV-HB-Hib vaccine work?

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b.

What is DTaP-IPV-HB-Hib vaccine used for?

DTaP-IPV-HB-Hib vaccine is indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and Haemophilus influenzae type b in infants and children.

Who makes DTaP-IPV-HB-Hib vaccine?

DTaP-IPV-HB-Hib vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is DTaP-IPV-HB-Hib vaccine also known as anything else?

DTaP-IPV-HB-Hib vaccine is also known as Hexyon®/Hexacima®.

What drug class is DTaP-IPV-HB-Hib vaccine in?

DTaP-IPV-HB-Hib vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTaP-IPV-HB-Hib vaccine in?

DTaP-IPV-HB-Hib vaccine is in Phase 3.

What are the side effects of DTaP-IPV-HB-Hib vaccine?

Common side effects of DTaP-IPV-HB-Hib vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability or fussiness, Drowsiness, Loss of appetite, Vomiting.

Related